EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Evaluating Donor-Derived Cell-Free DNA as a Non-Invasive Biomarker for Solid Organ Transplant Rejection: A Systematic Review and Meta-Analysis

Ευάγγελος Δ. Μαντιός

Aristotle University of Thessaloniki · 01.01.2026

DOI: 10.26262/heal.auth.ir.374481 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Aristotle University of Thessaloniki, erschienen am 01.01.2026. Verfasst von Ευάγγελος Δ. Μαντιός.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Donor-derived cell-free DNA (dd-cfDNA) has emerged as a promising non-invasive biomarker for detecting allograft injury in solid organ transplantation. Despite increasing clinical adoption, its diagnostic performance has been reported inconsistently across organs, rejection phenotypes and study designs. A systematic review and diagnostic test accuracy meta-analysis was conducted across kidney, heart, lung and liver transplantation. Studies reporting extractable 2×2 data for dd-cfDNA were included. Thresholds were standardised using clinically dominant values for each organ (0.5% and 1.0% for kidney; ~0.2% for heart; ~1% for lung). Pooled sensitivity and specificity were estimated using hierarchical bivariate random-effects models, complemented by Steinhauser multi-threshold modelling to incorporate all reported cutoffs. Forty-six studies were included in the qualitative synthesis and forty-three in the quantitative analysis. In kidney transplantation, pooled sensitivity and specificity were approximately 0.68 and 0.75 respectively at the 0.5% threshold and 0.50 and 0.81 at the 1.0% threshold. In heart transplantation, dd-cfDNA demonstrated moderate diagnostic accuracy at thresholds around 0.2%, with a pooled sensitivity of 0.71 and a pooled specificity of 0.76. Across organs, lower thresholds favoured sensitivity whereas higher thresholds improved specificity. Diagnostic performance was consistently higher for antibody-mediated rejection than for acute cellular rejection in kidney cohorts. Evidence for heart AMR and for lung and liver transplantation remained limited due to small study numbers and heterogeneous designs. Although dd-cfDNA provides a useful adjunct signal of graft injury, the methodological constraints of the current evidence base suggest that its accuracy in real-world settings is likely lower than previously reported. dd-cfDNA alone should not be used to trigger biopsy decisions without clinical context. Standardized prospective cohorts, consistent biopsy application and integration with complementary biomarkers are needed to define the biomarker’s role more precisely in transplant surveillance and diagnostic pathways.

Schlagwörter

donor-derived cell-free DNAallograft rejectionsolid organ transplantationnon-invasive biomarkersdiagnostic accuracykidney transplantationheart transplantationlung transplantationliver transplantationantibody-mediated rejection

Zitieren

APA

Μαντιός, Ε. Δ. (2026). Evaluating Donor-Derived Cell-Free DNA as a Non-Invasive Biomarker for Solid Organ Transplant Rejection: A Systematic Review and Meta-Analysis. Aristotle University of Thessaloniki. https://doi.org/10.26262/heal.auth.ir.374481

Vancouver

Μαντιός ΕΔ. Evaluating Donor-Derived Cell-Free DNA as a Non-Invasive Biomarker for Solid Organ Transplant Rejection: A Systematic Review and Meta-Analysis. Aristotle University of Thessaloniki. 2026. doi:10.26262/heal.auth.ir.374481

BibTeX
@article{2026,
  author = {Μαντιός, Ευάγγελος Δ.},
  title = {Evaluating Donor-Derived Cell-Free DNA as a Non-Invasive Biomarker for Solid Organ Transplant Rejection: A Systematic Review and Meta-Analysis},
  journal = {Aristotle University of Thessaloniki},
  year = {2026},
  doi = {10.26262/heal.auth.ir.374481}
}
Kostenlos starten →